ZYBERNO
Stock Report
Updated Jun 8, 2026

LadRx Corporation (LADX)

Healthcare • Over The Counter

$0.11

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
4.0/100
POOR BUSINESS
LadRx Corporation (LADX) scores 4/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-4,956.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

LadRx Corporation (LADX) stock report — Zyberno Score 4/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.11
Market Cap:$52.97K

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$153.97K
B. Profitability Assessment

Return Metrics (4)

ROA:-694.8%
Reinvestment Rate:0.2%
Fundamental Growth Rate (g):-10.8%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$6.78K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-579.7%
Latest Earnings Filed:2025-05-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.11x
Quick Ratio:0.11x
Cash Ratio:0.09x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-2,136,621.00
Cash And Cash Equivalents:206,948.00
Long Term Debt:$0.00
Net Debt:-$206.95K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$3.51M

Bottom Line Performance (3)

-$3.59M
Income Before Tax:$0.00
Ebitda Ttm:-3,506,614.00

Operating Expenses (5)

Operating Expenses:4,801,345.00
R And D Expense:771,214.00
Sga Expense:2,733,979.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$260.07K
Current Assets:$258.24K
Ppe Net:354.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:2,394,865.00
Current Liabilities:2,394,865.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:-$2.13M
Retained Earnings:-$490.82M
Common Stock:62,393,940.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,101,488.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:3,928.00
C. Cash Flow Analysis

Operating Activities (2)

-$1.86M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:4,291.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-7.25
-$7.25
Earnings Per Share Ttm:-$7.26

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.65

Book Value & Capital (2)

Book Value Per Share:-$4.31
Cash Per Share:0.42

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:10.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.2%
Fundamental Growth Rate (g):-10.8%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:LADX
Company Name:LadRx Corporation
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:Over The Counter
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:495.09K
Shares Outstanding Basic:495.09K
Shares Outstanding Diluted:495.09K

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-08 23:19:48 UTC
Data Timestamp:2026-06-08T23:19:48.485630
Scroll to Top